Skip to main content
Fig. 1 | BMC Rheumatology

Fig. 1

From: Effectiveness and safety of intravenous golimumab with and without concomitant methotrexate in patients with rheumatoid arthritis in the prospective, noninterventional AWARE study

Fig. 1

Mean change from baseline at Month 6 (a) and Month 12 (b) in CDAI score for IV golimumab with and without methotrexate (last observation carried forward for missing data) in biologic-naïve and biologic-experienced patients. CDAI Clinical Disease Activity Index, IV intravenous, SD standard deviation

Back to article page

BMC Rheumatology

ISSN: 2520-1026

Contact us